The history of the pharmacotherapy of obesity
https://doi.org/10.14341/probl13469
Abstract
The obesity epidemic is a major public health problem nowadays. The pathophysiology of obesity, which underlies its chronic, progressive, self-sustaining course, determines the difficulties in developing effective and safe methods for body weight control. The article is dedicated to the consideration of the evolution of conservative treatment of obesity, in particular, the history of pharmacotherapy of this disease, characterized by many ups and downs, is presented. The paper discusses, in chronological order, the emergence, efficacy, mechanisms of action, and described side effects of drugs that were investigated and used for weight loss at one time or another, as well as the reasons why many of them were subsequently withdrawn from the market. Until recently, long-term effective and safe pharmacotherapy of obesity remained an insurmountable challenge. Only in the last two decades has the understanding of the molecular mechanisms of appetite control reached a level that allows for a more productive search and development of promising drugs aimed at the pathogenetic treatment of obesity. This article discusses the status of currently available drugs for weight loss, as well as the prospects for drug treatment of obesity. The results of clinical trials of advanced therapeutic molecules, including gastrointestinal hormone receptor agonists, reinforce the belief that a breakthrough in the drug treatment of obesity is possible.
About the Authors
M. A. Berkovskaya
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Marina A. Berkovskaya, MD, PhD
1 Pogodinskaya street, 119435 Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи
O. Yu. Gurova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Olesya Yu. Gurova, MD, PhD
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи
E. V. Surkova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Elena V. Surkova, MD, PhD
Moscow
Competing Interests:
Elena V. Surkova, MD, PhD
V. V. Fadeev
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Valentin V. Fadeev, MD, ScD, professor, corresponding member of the RAS
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи
References
1. Who.int [Internet]. World Health Organization: Obesity and Overweight. WHO fact sheet №311 [updated March 2024]. Available from: www.who.int/mediacentre/factsheets/fs311/en
2. Zheng H, Echave P, Mehta N. Obesity-mortality link over the life course: the contribution of population compositional changes. Biodemography Soc Biol. 2020;66(1):50-68. doi: https://doi.org/10.1080/19485565.2020.1821597
3. Bluher M. Obesity: global epidemiology and pathogenesis. Nat. Rev. Endocrinol. 2019;15:288–298. doi: https://doi.org/10.1038/s41574-019-0176-8
4. Kheniser K, Saxon DR, Kashyap SR. Long-Term Weight Loss Strategies for Obesity. J Clin Endocrinol Metab. 2021;106(7):1854-1866. doi: https://doi.org/10.1210/clinem/dgab091
5. Carlsson LMS, Sjöholm K, Jacobson P, et al. Life expectancy after bariatric surgery in the Swedish Obese Subjects Study. N. Engl. J. Med. 2020;383:1535–1543. doi: https://doi.org/10.1056/NEJMoa2002449
6. Adams TD, Davidson LE, Litwin SE, et al. Weight and metabolic outcomes 12 years after gastric bypass. N. Engl. J. Med. 2017;377:1143–1155. doi: https://doi.org/10.1056/NEJMoa1700459
7. Haslam D. Weight management in obesity - past and present. Int J Clin Pract. 2016;70(3):206-217. doi: https://doi.org/10.1111/ijcp.12771
8. Papavramidou NS, Papavramidis ST, Christopoulou-Aletra H. Galen on obesity: etiology, effects, and treatment. World J Surg. 2004;28(6):631-635. doi: https://doi.org/10.1007/s00268-004-7458-5
9. Christopoulou-Aletra H, Papavramidou N. Methods used by the hippocratic physicians for weight reduction. World J Surg. 2004;28(5):513-517. doi: https://doi.org/10.1007/s00268-004-7373-9
10. Kryger MH. Sleep apnea. From the needles of Dionysius to continuous positive airway pressure. Arch Intern Med. 1983;143(12):2301-2303. doi: https://doi.org/10.1001/archinte.143.12.2301
11. Haslam D. The Weight of Obsession. A Brief but Wide, History, 2015. https://commonreader.wustl.edu/c/the-weight-of-obsession
12. Clapham JC, Arch JR. Thermogenic and metabolic antiobesity drugs: rationale and opportunities. Diabetes Obes Metab. 2007;9(3):259-275. doi: https://doi.org/10.1111/j.1463-1326.2006.00608.x
13. Rivlin RS. Therapy of obesity with hormones. N Engl J Med. 1975;292(1):26-29. doi: https://doi.org/10.1056/NEJM197501022920106
14. Weigle DS. Pharmacological therapy of obesity: past, present, and future. J Clin Endocrinol Metab. 2003;88(6):2462-2469. doi: https://doi.org/10.1210/jc.2003-030151
15. Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present--a pharmacological and clinical perspective. J Psychopharmacol. 2013;27(6):479-496. doi: https://doi.org/10.1177/0269881113482532
16. Gurtner HP. Aminorex and pulmonary hypertension. A review. Cor Vasa. 1985;27(2-3):160-171
17. Weintraub M. Long-term weight control study: conclusions. Clin Pharmacol Ther. 1992;51(5):642-646. doi: https://doi.org/10.1038/clpt.1992.76
18. Mark EJ, Patalas ED, Chang HT, et al. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine [published correction appears in N Engl J Med 1997 Nov 13;337(20):1483]. N Engl J Med. 1997;337(9):602-606. doi: https://doi.org/10.1056/NEJM199708283370904
19. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine [published correction appears in N Engl J Med 1997 Dec 11;337(24):1783]. N Engl J Med. 1997;337(9):581-588. doi: https://doi.org/10.1056/NEJM199708283370901
20. Pi-Sunyer FX. Heart valve lesions in patients treated with appetite suppressants. Obes Res. 1999;7(4):414-416. doi: https://doi.org/10.1002/j.1550-8528.1999.tb00426.x
21. Wee CC, Phillips RS, Aurigemma G, et al. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication [published correction appears in Ann Intern Med 2000 Jan 18;132(2):167]. Ann Intern Med. 1998;129(11 Pt 1):870-874. doi: https://doi.org/10.7326/0003-4819-129-11_part_1-199812010-00005
22. Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N Engl J Med. 1998;339(11):725-732. doi: https://doi.org/10.1056/NEJM199809103391103
23. Weissman NJ, Panza JA, Tighe JF, Gwynne JT. Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134(4):267-273. doi: https://doi.org/10.7326/0003-4819-134-4-200102200-00009
24. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000;343(25):1826-1832. doi: https://doi.org/10.1056/NEJM200012213432501
25. Araújo JR, Martel F. Sibutramine effects on central mechanisms regulating energy homeostasis. Curr Neuropharmacol. 2012;10(1):49-52. doi: https://doi.org/10.2174/157015912799362788
26. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis [published correction appears in BMJ. 2007 Nov 24;335(7629). doi: 10.1136/bmj.39406.519132.AD]. BMJ. 2007;335(7631):1194-1199. doi: https://doi.org/10.1136/bmj.39385.413113.25
27. James, W. Philip T. The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. European heart journal supplements 7. 2005; suppl_L:44-48.
28. Caterson ID, Finer N, Coutinho W, et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab. 2012;14(6):523-530. doi: https://doi.org/10.1111/j.1463-1326.2011.01554.x
29. Troshina EA, Ershova EV. Pharmacotherapy of obesity: what’s new? Problems of Endocrinology. 2018;64(4):270-276. (In Russ.). doi: https://doi.org/10.14341/probl9315
30. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients [published correction appears in Diabetes Care. 2004 Mar;27(3):856]. Diabetes Care. 2004;27(1):155-161. doi: https://doi.org/10.2337/diacare.27.1.155
31. Douglas IJ, Langham J, Bhaskaran K, et al. Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink. BMJ. 2013;346:f1936. doi: https://doi.org/10.1136/bmj.f1936
32. Robson PJ. Therapeutic potential of cannabinoid medicines. Drug Test Anal. 2014;6(1-2):24-30. doi: https://doi.org/10.1002/dta.1529
33. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials [published correction appears in Lancet. 2008 Feb 16;371(9612):558]. Lancet. 2007;370(9600):1706-1713. doi: https://doi.org/10.1016/S0140-6736(07)61721-8
34. Weissman NJ, Sanchez M, Koch GG, et al. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging. 2013;6(4):560-567. doi: https://doi.org/10.1161/CIRCIMAGING.112.000128
35. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebocontrolled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245-256. doi: https://doi.org/10.1056/NEJMoa0909809
36. Aronne LJ, Wadden TA, Peterson C, et al. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring). 2013;21(11):2163-2171. doi: https://doi.org/10.1002/oby.20584
37. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial [published correction appears in Lancet. 2011 Apr 30;377(9776):1494]. Lancet. 2011;377(9774):1341-1352. doi: https://doi.org/10.1016/S0140-6736(11)60205-5
38. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330-342. doi: https://doi.org/10.1038/oby.2011.330
39. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/ topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297-308. doi: https://doi.org/10.3945/ajcn.111.024927
40. Margulis AV, Mitchell AA, Gilboa SM, et al. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol. 2012;207(5):405. e1-405.e4057. doi: https://doi.org/10.1016/j.ajog.2012.07.008
41. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebocontrolled, phase 3 trial [published correction appears in Lancet. 2010 Aug 21;376(9741):594] [published correction appears in Lancet. 2010 Oct 23;376(9750):1392]. Lancet. 2010;376(9741):595-605. doi: https://doi.org/10.1016/S0140-6736(10)60888-4
42. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935-943. doi: https://doi.org/10.1002/oby.20309
43. Dahlberg S, Chang ET, Weiss SR, et al. Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review. Diabetes Metab Syndr Obes. 2022;15:3049-3067. doi: https://doi.org/10.2147/DMSO.S381652
44. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110-120. doi: https://doi.org/10.1038/oby.2010.147
45. Andermann ML, Lowell BB. Toward a Wiring Diagram Understanding of Appetite Control. Neuron. 2017;95(4):757-778. doi: https://doi.org/10.1016/j.neuron.2017.06.014
46. Müller TD, Finan B, Bloom SR, et al. Glucagonlike peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. doi: https://doi.org/10.1016/j.molmet.2019.09.010
47. Terrill SJ, Jackson CM, Greene HE, et al. Role of lateral septum glucagon-like peptide 1 receptors in food intake. Am J Physiol Regul Integr Comp Physiol. 2016;311(1):R124-R132. doi: https://doi.org/10.1152/ajpregu.00460.2015
48. van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2014;38(6):784-793. doi: https://doi.org/10.1038/ijo.2013.162
49. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. doi: https://doi.org/10.1056/NEJMoa1411892
50. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi: https://doi.org/10.1056/NEJMoa2032183
51. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. doi: https://doi.org/10.1001/jama.2021.3224
52. Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet. 2023;402(10403):705-719. doi: https://doi.org/10.1016/S0140-6736(23)01185-6
53. Chavda VP, Ajabiya J, Teli D, et al. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022;27(13):4315. doi: https://doi.org/10.3390/molecules27134315
54. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi: https://doi.org/10.1056/NEJMoa2206038
55. le Roux CW, Steen O, Lucas KJ, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162-173. doi: https://doi.org/10.1016/S2213-8587(23)00356-X
56. Wharton S, Blevins T, Connery L, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389(10):877-888. doi: https://doi.org/10.1056/NEJMoa2302392
57. Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, activecontrolled, phase 2 trial. Lancet. 2023;402(10403):720-730. doi: https://doi.org/10.1016/S0140-6736(23)01163-7
58. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. doi: https://doi.org/10.1016/j.cmet.2022.07.013
59. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, doubleblind, placebo-controlled, randomised, multipleascending dose trial. Lancet. 2022;400(10366):1869-1881. doi: https://doi.org/10.1016/S0140-6736(22)02033-5
60. Jastreboff АM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. doi: https://doi.org/10.1056/NEJMoa2301972
Supplementary files
Review
For citations:
Berkovskaya M.A., Gurova O.Yu., Surkova E.V., Fadeev V.V. The history of the pharmacotherapy of obesity. Problems of Endocrinology. 2025;71(2):82-92. (In Russ.) https://doi.org/10.14341/probl13469
Views:
595
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
